Evidence map›Paper›PMID 27876044›Full record

ArticleBMC biotechnology2016

Generation of monoclonal antibodies against native viral proteins using antigen-expressing mammalian cells for mouse immunization.

Natalie Rose, Carlos Augusto Pinho-Nascimento, Alessia Ruggieri, Paola Favuzza, Marco Tamborrini, Hanna Roth, Marcia Terezinha Baroni de Moraes, Hugues Matile, Thomas Jänisch, Gerd Pluschke and 1 more

Open access · goldAbstract read
In one paragraph

Article in BMC biotechnology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.5field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 6 institutions in 3 countries.

Natalie RoseSwiss Tropical and Public Health Institute, Molecular Immunology, Basel, Switzerland.
Carlos Augusto Pinho-NascimentoBiology Institute, Fluminense Federal University, Laboratory of Molecular Virology, Niterói, Brazil.
Alessia RuggieriDepartment of Infectious Diseases, University of Heidelberg, Molecular Virology, Heidelberg, Germany.
Paola FavuzzaSwiss Tropical and Public Health Institute, Molecular Immunology, Basel, Switzerland.
Marco TamborriniSwiss Tropical and Public Health Institute, Molecular Immunology, Basel, Switzerland.
Hanna RothDepartment of Infectious Diseases, University of Heidelberg, Molecular Virology, Heidelberg, Germany.
Marcia Terezinha Baroni de MoraesOswaldo Cruz Institute, Fiocruz, Laboratory of comparative and environmental Virology, Rio de Janeiro, Brazil.
Hugues MatileSwiss Tropical and Public Health Institute, Molecular Immunology, Basel, Switzerland.
Thomas JänischSection Clinical Tropical Medicine, Department of Infectious Diseases, Heidelberg University Hospital, Heidelberg, Germany.
Gerd PluschkeSwiss Tropical and Public Health Institute, Molecular Immunology, Basel, Switzerland.
Katharina RöltgenSwiss Tropical and Public Health Institute, Molecular Immunology, Basel, Switzerland. Katharina.roeltgen@unibas.ch.
University of Basel · CHHeidelberg University · DEFundação Oswaldo Cruz · BRSwiss Tropical and Public Health Institute · CHUniversidade Federal Fluminense · BRUniversity Hospital Heidelberg · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundDue to their rising incidence and progressive geographical spread, infections with mosquito-borne viruses, such as dengue (DENV), chikungunya and zika virus, have developed into major public health challenges. Since all of these viruses may cause similar symptoms and can occur in concurrent epidemics, tools for their differential diagnosis and epidemiological monitoring are of urgent need.

resultsHere we report the application of a novel strategy to rapidly generate monoclonal antibodies (mAbs) against native viral antigens, exemplified for the DENV nonstructural glycoprotein 1 (NS1). The described system is based on the immunization of mice with transfected mammalian cells expressing the target antigens in multiple displays on their cell surface and thereby presenting them efficiently to the host immune system in their native conformation. By applying this cell-based approach to the DENV NS1 protein of serotypes 1 (D1NS1) and 4 (D4NS1), we were able to rapidly generate panels of DENV NS1 serotype cross-reactive, as well as D1NS1- and D4NS1 serotype-specific mAbs. Our data show that the generated mAbs were capable of recognizing the endogenous NS1 protein in DENV-containing biological samples.

conclusionThe use of this novel immunization strategy, allows for a fast and efficient generation of hybridoma cell lines, producing mAbs against native viral antigens. Envisaged applications of the mAbs include the development of test platforms enabling a differentiation of the DENV serotypes and high resolution immunotyping for epidemiological studies.

Indexed as

AnimalsAntibodies, MonoclonalAntigen-Presenting CellsAntigens, ViralDrug DesignDrug Evaluation, PreclinicalEpitope MappingHEK293 CellsHumansImmunizationImmunoassayMiceViral Nonstructural ProteinsAntibodies, MonoclonalAntigens, ViralNS1 protein, dengue-1 virusViral Nonstructural ProteinsDengue virusHEK cellsHybridoma technologyMonoclonal antibodiesMouse immunizationNS1 proteinTransfection

Identifiers

PMID27876044
PMCPMC5120561
OpenAlexW2556171849

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.